As of close of business last night, Caris Life Sciences Inc’s stock clocked out at $27.06, down -8.40% from its previous closing price of $29.54. In other words, the price has decreased by -$8.40 from its previous closing price. On the day, 0.73 million shares were traded. CAI stock price reached its highest trading level at $30.14 during the session, while it also had its lowest trading level at $26.97.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on July 14, 2025, initiated with a Outperform rating and assigned the stock a target price of $32.
On July 14, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $32.
On July 14, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $31.JP Morgan initiated its Overweight rating on July 14, 2025, with a $31 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 20 ’25 when Denton John Russel bought 7,500 shares for $21.00 per share. The transaction valued at 157,500 led to the insider holds 123,591 shares of the business.
Brille Brian J bought 30,000 shares of CAI for $630,000 on Jun 20 ’25. The insider now owns 162,428 shares after completing the transaction at $21.00 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAI now has a Market Capitalization of 8210139136 and an Enterprise Value of 3586043136. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.62. Its current Enterprise Value per Revenue stands at 7.925 whereas that against EBITDA is -19.427.
Stock Price History:
Over the past 52 weeks, CAI has reached a high of $33.41, while it has fallen to a 52-week low of $25.40. The 50-Day Moving Average of the stock is -2.94%, while the 200-Day Moving Average is calculated to be -2.94%.
Shares Statistics:
It appears that CAI traded 1.46M shares on average per day over the past three months and 602190 shares per day over the past ten days. A total of 277.93M shares are outstanding, with a floating share count of 121.38M. Insiders hold about 48.50% of the company’s shares, while institutions hold 5.20% stake in the company. Therefore, it implies a Short% of Shares Outstanding of 1360785 and a Short% of Float of 1.11.
Earnings Estimates
The stock of Caris Life Sciences Inc (CAI) is currently being evaluated by 4 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.11 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.71 and -$1.06 for the fiscal current year, implying an average EPS of -$0.86. EPS for the following year is $0.17, with 6.0 analysts recommending between $0.44 and -$0.07.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $147.57M. There is a high estimate of $152M for the next quarter, whereas the lowest estimate is $145.25M.
Based on 8 analysts’ estimates, the company’s revenue will be $939.25M in the next fiscal year. The high estimate is $980.45M and the low estimate is $900M.
